Agree.
Been some really good preclinical announcements, (recent kidney cancer preclinical was many months in the making) but the market doesn't seem to care much at all.
Given the current macro environment(which wasn't a problem last year) and affecting Biotechs more so than the resource sector, The Board may want to re-assess how to protect its value from sliding further and get new investors on board.
Our recent discussion suggests Clinical results and partnership announcements should help get new investors on board.
RAC - Charts & Price Action, page-11128
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.45 |
Change
0.030(2.11%) |
Mkt cap ! $247.1M | |||
| Open | High | Low | Value | Volume |
| $1.43 | $1.45 | $1.40 | $163.8K | 115.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | $1.44 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.45 | 31396 | 1 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| RAC (ASX) Chart |